BMG Pharma and HTL sign a development agreement

The agreement between BMG Pharma and HTL will allow BMG Pharma to develop and commercialize injectable products with Sodium Hyaluronate Lipoate Formate (SHLF). BMG Pharma through its patented Hyaluromimethic® Technology works on SHLF to develop solutions in aesthetic dermatology, ophthalmology, and arthrosis.

– Thanks to this agreement, BMG Pharma will globally develop new formulations of its injectable products, always with high levels of quality, stability, and safety standards.

Read more below

English

French